Despite the tissue specificity of MAP's cancer risk phenotype, recent evidence indicates that this condition also causes elevated somatic mutation rates in a wider variety of human cell types, including blood (Robinson et al. 2022), which might be why some studies have found MUTYH variants to be associated with increased risk of extracolonic cancers (Zhang et al. 2006; Beiner et al. 2009; Vogt et al. 2009; Win et al. 2016; Villy et al. 2022). Here, MUTYH is linked to cancer.